INM
InMed Pharmaceuticals, Inc.
( )
company profile
InMed Pharmaceuticals is a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. They also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.
Rare cannabinoids are an emerging class of compounds which are gaining interest for their potential medical benefits. InMed has initiated three pharmaceutical programs – a Phase 2 clinical trial for epidermolysis bullosa, and two preclinical programs in glaucoma and neurodegenerative disease.
Unlike natural cannabinoids isolated from the plant which are not patentable, InMed’s proprietary cannabinoid analogs are patentable and are recognized as new chemical entities (NCEs). These analogs are expected to offer similar or improved therapeutic effects compared to their parent (naturally occurring) cannabinoid with modifications that may make them preferred candidates to treat specific diseases. They are screening these analogs for their therapeutic properties and pharmaceutical development.
InMed’s subsidiary, BayMedica, is producing a portfolio of premium rare cannabinoids as raw ingredients for your health and wellness products. They have engineered bioidentical cannabinoids with high purity and consistency, and free of THC.They currently manufacture the rare, minor cannabinoids cannabichromene (CBC), tetrahydrocannabivarin (d9-THCV), cannabidivarin (CBDV) and cannabicitran (CBT) which are available for B2B purchase. They recently reported $1M in quarterly revenues in Q3, which was the first time they exposed this level from the sales of rare cannabinoids to the Health and Wellness (“H&W”) sector, representing a 120% increase over 2Q sales.
vista's key points
- InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs.
- InMed has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.
- Rare cannabinoids are an emerging class of compounds which are gaining interest for their potential medical benefits.
- InMed is researching the therapeutic benefits of several rare cannabinoids and have produced a growing library of rare cannabinoid analogs for development.
- InMed has initiated three pharmaceutical programs – a Phase 2 clinical trial for epidermolysis bullosa (EB), and two preclinical programs in glaucoma and neurodegenerative disease.
- InMed Completed enrollment in Phase 2 Clinical Trial for epidermolysis bullosa; data readout expected during calendar 3Q 2023.
- InMed has expanded its pharmaceutical pipeline to investigate rare cannabinoids for their potential in treating neurodegenerative disease such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease and others.
- InMed sponsored research, entitled "Cannabinoids modulate cytotoxicity and neuritogenesis in Amyloid-beta-treated neuronal cells", demonstrated the ability of a specific rare cannabinoid ("pCBx") in InMed's 900 Series library of potential candidates that reduces amyloid toxicity and tau protein expression while enhancing neuronal cell growth and neuritogenesis markers in vitro, all considered to be important targets in the potential treatment of neurodegenerative diseases such as Alzheimer's.
- Published a peer-reviewed study showing the anti-inflammatory potential of rare cannabinoids.
- InMed's wholly owned subsidiary, BayMedica, produces highly pure rare cannabinoids d9-THCV, CBC, CBDV and CBT for the consumer health and wellness industry.
- InMed's BayMedica continues to be a leading producer of cannabichromene (CBC) with increased revenue in the last 3Q's,120% quarter-over-quarter revenue growth in Q3 & continues to evaluate strategic options/long-term supply agreements for this business segment.
- At March 31, 2023, InMed's total issued and outstanding shares were 3,328,191.
- On March 13, InMed announced that a peer-reviewed scientific study entitled “Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway” has been published in the International Journal of Molecular Sciences.
- At March 31, 2023, Inmed's cash, cash equivalents and short-term investments were $9.6 million, which compares to $6.2 million at June 30, 2022.
VISTA'S PROGRESS REPORT
InMed Pharmaceuticals (“InMed”) is a publicly traded company on the Nasdaq that trades under the symbol INM. InMed is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. They also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. InMed pharmaceutical programs include a Phase 2 clinical trial studying the safety and efficacy of cannabinol (CBN) cream for epidermolysis bullosa and preclinical programs in glaucoma and neurodegenerative disease.InMed’s rare cannabinoids are being applied across a spectrum of uses – from pharmaceutical development to wholesale sales to the consumer health and wellness sector. In addition, a wholly owned subsidiary of InMed, BayMedica, produces highly pure rare cannabinoids d9-THCV, CBC, CBDV and CBT for the consumer health and wellness industry.
View InMed’s latest powerpoint presentation here.
On June 1, InMed announced that results from a neurodegenerative disease study was presented in a scientific poster at the Canadian Neuroscience Meeting in Montreal from May 28-31, 2023. The InMed sponsored research, entitled “Cannabinoids modulate cytotoxicity and neuritogenesis in Amyloid-beta-treated neuronal cells”, demonstrated the ability of a specific rare cannabinoid (“pCBx”) in InMed’s 900 Series library of potential candidates that reduces amyloid toxicity and tau protein expression while enhancing neuronal cell growth and neuritogenesis markers in vitro, all considered to be important targets in the potential treatment of neurodegenerative diseases such as Alzheimer’s. The research was conducted in the laboratory of Dr. Ujendra Kumar and Dr. Rishi Somvanshi of the faculty of Pharmaceutical Sciences at the University of British Columbia. Studies have shown that cannabinoids, via their endocannabinoid receptors (CB1R and CB2R) that naturally occur in the human body and brain, reduce amyloid-beta (“Aβ”) toxicity, decrease p-tau protein expression and provide neurite outgrowth, thus improving neuronal viability and function. The results presented demonstrate the anti-apoptotic effects of pCBx and its role in neuritogenesis in the cells of neuronal origin and support the role of pCBx as a potential therapeutic intervention in neurodegenerative diseases.
On May 15, InMed announced financial results for the third quarter of the fiscal year 2023 (“FY 3Q23”) which ended March 31, 2023. InMed confirmed cash, cash equivalents and short-term investments were $9.6 million, which compares to $6.2 million at June 30, 2022. InMed highlighted that the Company Completed enrollment in Phase 2 Clinical Trial; data readout expected during calendar 3Q 2023, 120% quarter-over-quarter revenue growth in the commercial BayMedica subsidiary, & that they Published a peer-reviewed study showing the anti-inflammatory potential of rare cannabinoids. Eric A. Adams, President and CEO of InMed stated, “The third quarter of fiscal year 2023 was an important period for InMed, as we achieved several key milestones across our different business segments, including completing enrollment in our Phase 2 clinical trial for epidermolysis bullosa, marking the first time cannabinol (“CBN”) has completed a Phase 2 clinical trial. We look forward to the data read out during 3Q and will then be in a better position to evaluate our strategic opportunities for the program. We are increasingly excited about the data we are seeing in our preclinical ocular and neurodegenerative disease programs where we are researching proprietary cannabinoid analogs in the treatment of various indications. We also hit another significant milestone in our commercial BayMedica subsidiary, surpassing $1M in quarterly revenues for the first time from the sales of rare cannabinoids to the Health and Wellness (“H&W”) sector, representing a 120% increase over 2Q sales. In the last few months we have seen a noticeable increase in awareness, understanding and adoption of rare cannabinoids in the H&W sector, evidenced by leading companies expanding their product lines to include new formats and formulations using rare cannabinoids such as the non-psychoactive ingredient cannabichromene (“CBC”). We are encouraged by two consecutive periods of significant quarter over quarter revenue growth. We will continue to support growth in a fiscally prudent manner in this relatively nascent market, where product demand can be unpredictable. The combination of a pharmaceutical drug development pipeline, together with a revenue generating commercial operation that will be contributing to extending our cash runway makes InMed a unique company within the rare cannabinoid space.” Learn more here.
On March 13, InMed announced that a peer-reviewed scientific study entitled “Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway” has been published in the International Journal of Molecular Sciences. This is the second such Company-sponsored study to demonstrate the anti-inflammatory effects of rare cannabinoids and their potential application for the treatment of skin conditions such as atopic dermatitis, psoriasis, pruritus, and acne. The study, conducted in collaboration with Dr. Mauro Maccarrone at the Università degli Studi dell’Aquila, investigates the anti-inflammatory effects of the rare cannabinoids, cannabichromene (CBC), Δ9-tetrahydrocannabivarin (THCV), cannabigerol (CBG) and cannabigerolic acid (CBGA) on inflamed human keratinocytes (HaCaT cells) and elucidates the potential mechanism of action associated with these compounds in the skin.
Read Morevista's key points
- InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs.
- InMed has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.
- Rare cannabinoids are an emerging class of compounds which are gaining interest for their potential medical benefits.
- InMed is researching the therapeutic benefits of several rare cannabinoids and have produced a growing library of rare cannabinoid analogs for development.
- InMed has initiated three pharmaceutical programs – a Phase 2 clinical trial for epidermolysis bullosa (EB), and two preclinical programs in glaucoma and neurodegenerative disease.
- InMed Completed enrollment in Phase 2 Clinical Trial for epidermolysis bullosa; data readout expected during calendar 3Q 2023.
- InMed has expanded its pharmaceutical pipeline to investigate rare cannabinoids for their potential in treating neurodegenerative disease such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease and others.
- InMed sponsored research, entitled "Cannabinoids modulate cytotoxicity and neuritogenesis in Amyloid-beta-treated neuronal cells", demonstrated the ability of a specific rare cannabinoid ("pCBx") in InMed's 900 Series library of potential candidates that reduces amyloid toxicity and tau protein expression while enhancing neuronal cell growth and neuritogenesis markers in vitro, all considered to be important targets in the potential treatment of neurodegenerative diseases such as Alzheimer's.
- Published a peer-reviewed study showing the anti-inflammatory potential of rare cannabinoids.
- InMed's wholly owned subsidiary, BayMedica, produces highly pure rare cannabinoids d9-THCV, CBC, CBDV and CBT for the consumer health and wellness industry.
- InMed's BayMedica continues to be a leading producer of cannabichromene (CBC) with increased revenue in the last 3Q's,120% quarter-over-quarter revenue growth in Q3 & continues to evaluate strategic options/long-term supply agreements for this business segment.
- At March 31, 2023, InMed's total issued and outstanding shares were 3,328,191.
- On March 13, InMed announced that a peer-reviewed scientific study entitled “Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway” has been published in the International Journal of Molecular Sciences.
- At March 31, 2023, Inmed's cash, cash equivalents and short-term investments were $9.6 million, which compares to $6.2 million at June 30, 2022.
exclusive content
Vista Partners creates exclusive content based on the ongoing research of companies included in the VP Watchlist.
vp watchlist
The VP Watchlist contains current coverage companies that deserve consideration for short term and long term portfolio additions.
recent news
-
InMed's Neurodegenerative Disease Study Presented at Canadian...
1 June 2023 | 11:30 am
-
InMed to Participate in Upcoming Virtual Investor...
24 May 2023 | 10:51 pm
-
InMed to Participate in Fireside Chat with...
18 May 2023 | 9:00 pm
Interviews
Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities.
Get Free Email Updatesvideos
- InMed Pharmaceuticals (NASDAQ: INM) – Addressing The Increasing Demand For Rare Cannabinoids
- What are Cannabinoid Analogs and Why are they Important?
- How Alzheimer’s Changes the Brain
- InMed Pharmaceuticals (NASDAQ: INM) “Addressing The Increasing Demand For Rare Cannabinoids”
- How Cannabis Legalization Is Changing The Workplace
- InMed Pharmaceuticals (INM) “Accelerating The Commercialization of Rare Cannabinoids” 9-21-21 Tribe Event!
- InMed’s IntegraSyn™ – a flexible, high yield & cost-effective cannabinoid manufacturing system